Therefore, our study identifies PPDPF as a negative regulator of lipogenesis by inhibiting mTOR-S6K-SREBP1 signaling and provides a promising therapeutic candidate for NAFLD. The gene discussed is RPS6KB1; the disease is metabolic dysfunction-associated steatotic liver disease.